Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2016 - 2026)

Amphastar Pharmaceuticals has reported Non-Current Assets over the past 13 years, most recently at $353.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 2.64% year-over-year to $353.7 million; the TTM value through Dec 2025 reached $353.7 million, up 2.64%, while the annual FY2025 figure was $353.7 million, 2.64% up from the prior year.
  • Non-Current Assets for Q4 2025 was $353.7 million at Amphastar Pharmaceuticals, roughly flat from $353.5 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $899.3 million in Q3 2023 and troughed at $259.8 million in Q3 2022.
  • A 5-year average of $420.3 million and a median of $321.6 million in 2023 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 246.15% in 2023 and later crashed 63.58% in 2024.
  • Year by year, Non-Current Assets stood at $271.5 million in 2021, then fell by 2.55% to $264.6 million in 2022, then grew by 19.3% to $315.6 million in 2023, then increased by 9.18% to $344.6 million in 2024, then grew by 2.64% to $353.7 million in 2025.
  • Business Quant data shows Non-Current Assets for AMPH at $353.7 million in Q4 2025, $353.5 million in Q3 2025, and $354.7 million in Q2 2025.